Literature DB >> 23590019

Reliability and validity of migraine disability assessment questionnaire-Thai version (Thai-MIDAS).

Piman Seethong1, Akarin Nimmannit, Rungsan Chaisewikul, Naraporn Prayoonwiwat, Wattanachai Chotinaiwattarakul.   

Abstract

OBJECTIVE: To assess the validity and test-retest reliability of a Thai translation of the Migraine Disability Assessment (MIDAS) Questionnaire in Thai patients with migraine. MATERIAL AND
METHOD: Migraineurs from the Headache Clinic in Siriraj Hospital were recruited and asked to complete a 13-weeks diary and answered the Thai-MIDAS at once. Some participants were asked to provide the 2nd Thai-MIDAS in the next 2 weeks for test-retest reliability.
RESULTS: Ninety-three patients had completed the 13-weeks diaries. Age range was 18-58 years with mean 37.69 +/- 9.60 years. All 5 items and the total score of Thai-MIDAS were moderately correlated with data from 13-weeks diary (Spearman's correlation coefficient = 0.32-0.62). The test-retest reliability of the total score of Thai-MIDAS in 30 patients demonstrated a highly reliable degree of intraclass correlation (ICC = 0.76, 95% CI 0.49-0.88).
CONCLUSION: The present study reveals that the Thai-MIDAS has satisfactory validity and reliability in comparison with the original English MIDAS version.

Entities:  

Mesh:

Year:  2013        PMID: 23590019

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  2 in total

1.  Translation, cross-cultural adaptation and reliability of the German version of the migraine disability assessment (MIDAS) questionnaire.

Authors:  Thomas Benz; Susanne Lehmann; Andreas R Gantenbein; Peter S Sandor; Walter F Stewart; Achim Elfering; André G Aeschlimann; Felix Angst
Journal:  Health Qual Life Outcomes       Date:  2018-03-09       Impact factor: 3.186

2.  Validity and reliability of the Portuguese version of the modified Migraine Disability Assessment.

Authors:  Pedro L Ferreira; Isabel Luzeiro; Margarida Lopes; André Jorge; Bruno Silva; Lara Ferreira
Journal:  BMC Neurol       Date:  2021-02-06       Impact factor: 2.474

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.